Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.09.21	New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV (GlobeNewswire)
19.09.21	ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC (GlobeNewswire)
14.09.21	Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics (GlobeNewswire)
09.09.21	Sanofi: Phase 3 Trial With Rilzabrutinib Fails To Meet Endpoints In Treatment Of Pemphigus (RTTNews)
09.09.21	Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus (GlobeNewswire)
08.09.21	Sanofi To Buy Rezurock Developer Kadmon In $1.9 Bln Cash Deal - Quick Facts (RTTNews)
08.09.21	Sanofi to acquire Kadmon to further strengthen growth of transplant business (GlobeNewswire)
30.08.21	Regeneron : Phase 3 Trial Of Dupixent On Atopic Dermatitis Meets Primary And Secondary Endpoints (RTTNews)
30.08.21	Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in chi (GlobeNewswire)
06.08.21	FDA Approves Nexviazyme For Treatment Of Pompe Disease (RTTNews)
06.08.21	FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease (GlobeNewswire)
05.08.21	Regeneron/Sanofi's Libtayo Combined With Chemo Reduced Death By 29% In Non-small Cell Lung Cancer (RTTNews)
05.08.21	Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer (GlobeNewswire)
03.08.21	Sanofi To Acquire Translate Bio In Deal Valued At Approx. $3.2 Bln - Quick Facts (RTTNews)
03.08.21	Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development (GlobeNewswire)
29.07.21	Online availability of Sanofi’s half-year financial report for 2021 (GlobeNewswire)
29.07.21	Sanofi Q2 Profit Plunges On Absence Of Prior Year One-time Gain; Lifts FY Profit Outlook (RTTNews)
29.07.21	Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI (GlobeNewswire)
29.07.21	Regeneron, Sanofi: Phase 3 Trial On Dupixent Met Key Endpoints At 24 Weeks (RTTNews)
29.07.21	Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients (GlobeNewswire)
27.07.21	Biotech Stocks Facing FDA Decision In August 2021 (RTTNews)
13.07.21	Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris (GlobeNewswire)
29.06.21	Sanofi Launches Vaccines MRNA Center Of Excellence; To Invest €400 Mln Annually (RTTNews)
29.06.21	Sanofi launches dedicated vaccines mRNA Center of Excellence (GlobeNewswire)
28.06.21	Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial (GlobeNewswire)
28.06.21	Regeneron, Sanofi: EMA To Update Dupixent SmPC With Long-term Safety Data (RTTNews)
28.06.21	Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis (GlobeNewswire)
25.06.21	Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes (GlobeNewswire)
25.06.21	Regeneron : EC Approves Libtayo For First-line Treatment Of Advanced Non-small Cell Lung Cancer (RTTNews)
25.06.21	Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma (GlobeNewswire)
25.06.21	Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with =50% PD-L1 expression (GlobeNewswire)
22.06.21	Sanofi Pasteur, Translate Bio Initiate Phase 1 Trial Of MRNA Influenza Vaccine (RTTNews)
18.06.21	EC Approves Sanofi's Aubagio For Treatment Of Pediatric Patients With RRMS (RTTNews)
18.06.21	European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis (GlobeNewswire)
11.06.21	New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious a (GlobeNewswire)
08.06.21	Sanofi Launches Global Employee Share Ownership Plan (RTTNews)
07.06.21	Sanofi launches its new global employee share ownership plan (GlobeNewswire)
04.06.21	Sanofi Partners With Academic Cooperative Groups To Study Amcenestrant In Breast Cancer (RTTNews)
04.06.21	Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer (GlobeNewswire)
03.06.21	Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects (GlobeNewswire)
01.06.21	Sanofi, Merck Announce Availability Of Six-in-one Pediatric Combination Vaccine Vaxelis In The U.S. (RTTNews)
01.06.21	Sanofi Halts Clinical Program In ADPKD As Venglustat Trial Failed To Meet Futility Criteria (RTTNews)
01.06.21	Sanofi provides update on venglustat clinical program (GlobeNewswire)
27.05.21	Sanofi, GSK Initiate Phase 3 Clinical Efficacy Study Of COVID-19 Vaccine Candidate (RTTNews)
27.05.21	Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate (GlobeNewswire)
24.05.21	Regeneron : Libtayo Gets Positive CHMP Opinion For Treatment Of Two Advanced Cancers (RTTNews)
19.05.21	Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting (GlobeNewswire)
19.05.21	Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer (GlobeNewswire)
17.05.21	Regeneron : Phase 3 Data Show Dupixent Reduces Asthma Attacks And Improves Lung Function In Children (RTTNews)
17.05.21	Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

mehr

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
29.12.24		Roche-CEO bescheinigt Pharmakonzern gesundes Geschäft
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Dow Jones aktuell: Dow Jones verliert am Freitagnachmittag
27.12.24		Schwacher Wochentag in New York: Dow Jones verbucht am Freitagmittag Verluste
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester